Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.

Date publication

février 2001

Journal

Journal of the National Cancer Institute

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier , Pr WESTEEL Virginie

Tous les auteurs :
Pujol JL, Daurès JP, Rivière A, Quoix E, Westeel V, Quantin X, Breton JL, Lemarié E, Poudenx M, Milleron B, Moro D, Debieuvre D, Le Chevalier T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/11181777

Résumé

The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC). To determine whether drug intensification improves survival of patients with extensive SCLC, we compared this treatment with a four-drug regimen containing EP plus cyclophosphamide and 4'-epidoxorubicin (PCDE).

Mots clés

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Carcinoma, Small Cell, drug therapy, Cisplatin, administration & dosage, Cyclophosphamide, administration & dosage, Doxorubicin, administration & dosage, Etoposide, administration & dosage, Female, France, Humans, Lung Neoplasms, drug therapy, Male, Middle Aged, Proportional Hazards Models, Quality of Life, Risk, Surveys and Questionnaires, Survival Analysis, Treatment Outcome

Référence

J. Natl. Cancer Inst.. 2001 Feb;93(4):300-8